Date: 2015-03-31
Type of information: Nomination
Compound:
Company: Sarepta Therapeutics (USA - MA)
Therapeutic area: Rare diseases - Genetic diseases - Neuromuscular diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On March 31, 2015, Sarepta Therapeutics announced the appointment of Edward Kaye, M.D., the company’s Chief Medical Officer (CMO), as interim Chief Executive Officer (CEO) effective immediately. He replaces Christopher Garabedian, who resigned as President and Chief Executive Officer and as a member of the Board, also effective immediately. Dr. Kaye, who will continue in a dual capacity as CEO and CMO while the company conducts a search for a new full-time CEO, will focus his efforts on heading the regulatory and clinical process for the company’s lead product candidate, eteplirsen, and follow on “exon” drug candidates for Duchenne Muscular Dystrophy (DMD).
Dr. Kaye has been Sarepta’s CMO since June of 2011, during which time he has been responsible for the company’s medical and clinical operations. He was previously Group Vice President of Clinical Development at Genzyme Corporation, one of the most successful biotechnology companies in the United States, from April 2007 to June 2011, where he supervised clinical development programs for rare diseases, including lysosomal storage diseases and genetic neurological disorders. Prior to this, Dr. Kaye held various roles at Genzyme Corporation since 2001, including Vice President of Medical Affairs for Lysosomal Storage Diseases, Vice President of Clinical Research and Interim Head of PGH Global Medical Affairs.
Financial terms:
Latest news:
